Figure 4: Experimental validation of protein modules in KRAS-Dep cells.
From: Reconstructing targetable pathways in lung cancer by integrating diverse omics data
(a) KRAS influences total and phosphorylated protein level of potential druggable kinases LCK and MET in KRAS-Dep cell lines. Knockdown of KRAS with two independent siRNAs reduces phosphorylation levels of LCK, MET, PAK1/2 in H441 cell line. KRAS-KD also reduced total protein levels of LCK and MET but not PAK1/2. (b) LCK influences PAK1/PAK2 activation in KRAS-Dep cell lines. Knockdown of LCK using two independent siRNAs reduces phosphorylation levels of PAK1/2 but not their protein level in H441 KRAS-Dep cell line. (c) PAK1/2 are downstream of LCK in KRAS-Dep cell lines. PAK1/2 knockdown does not affect phosphorylation or protein level of LCK in H441-Dep cell line. (d) LCK knockdown increases the level of cleaved PARP and caspase-3, markers of apoptosis in H441 KRAS-Dep cell line.
